Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
General21 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General18 hours agoRegional house price growth outstrips capital cities
-
General14 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
Noosa News14 hours agoCamels help eradicate invasive prickly acacia in outback Queensland trial